Adjunctive Treatment With Avacopan, an Oral C5a Receptor Inhibitor, in Patients With Antineutrophil Cytoplasmic Antibody–Associated Vasculitis

Adjunctive Treatment With Avacopan, an Oral C5a Receptor Inhibitor, in Patients With Antineutrophil Cytoplasmic Antibody–Associated Vasculitis

Objective This study aimed to evaluate the safety of avacopan, an orally administered C5a receptor inhibitor, for the treatment of antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis in addition to standard‐of‐care (SOC) treatment with glucocorticoids with cyclophosphamide or rituximab....

Full description

Bibliographic Details
Main Authors: Peter A. Merkel, John Niles, Richard Jimenez, Robert F. Spiera, Brad H. Rovin, Andrew Bomback, Christian Pagnoux, Antonia Potarca, Thomas J. Schall, Pirow Bekker, for the CLASSIC Investigators
Format: Article
Language:English
Published: Wiley 2020-11-01
Series:ACR Open Rheumatology
Online Access:https://doi.org/10.1002/acr2.11185

Internet

https://doi.org/10.1002/acr2.11185

Similar Items